According to a recent article in Medscape, the treatment of people with obesity (but without diabetes) with the glucagon-like peptide-1 (GLP-1) agonist semaglutide led to beneficial changes in body mass index (BMI), glycemic control, and other clinical measures.
This collectively cut the calculated risk for possible future development of Type 2 diabetes in study participants by more than half, based on data from two pivotal trials that compared semaglutide with placebo. The findings “suggest that semaglutide could help prevent Type 2 diabetes in people with overweight or obesity,” said W. Timothy Garvey, MD, in a presentation at the European Association for the Study of Diabetes 2022 Annual Meeting.
To read more, CLICK HERE.
